R&D channel feed – Endpoints News

R&D channel feed

Kadmon sticks a $100M toe in chilly market waters

9 years ago

Santhera’s Duchenne drug hits a roadblock at the FDA, and one analyst sees another bad sign for Sarepta

9 years ago

And then there were 4: Juno adds another victim in CAR-T death tally

9 years ago

Polaris is piecing together a new, $400M-plus biotech fund as good times roll

9 years ago

Biosimilars go 2-0 in an FDA double-header favoring Novartis, Amgen

9 years ago

The 15 top R&D spenders in the global biopharma business: 2016

9 years ago

Merck vet Michael Rosenblatt joins R&D exodus to the startup world

9 years ago

Periscope: Unsuccessful on Nasdaq, GenSight finds a home on Paris exchange

9 years ago

In a stunner, FDA immediately drops its hold on Juno’s lead CAR-T

9 years ago

Merck triggers a new round of layoffs in R&D reorganization, pushing more jobs into Cambridge, San Francisco

9 years ago

Sage claims another big win on a small study, this time for postpartum depression

9 years ago

$42M in, Flagship startups merge into one immuno-microbiome platform with multiple targets

9 years ago

Shire gains a delayed FDA OK for ‘blockbuster’ dry eye drug lifitegrast

9 years ago

CytRx concedes that its only drug flunked a PhIII sarcoma test, routing shares

9 years ago

Periscope: Ex-Baxalta exec David Meek takes Paris-based helm for Ipsen

9 years ago

I/O enthusiast Servier signs up for an $807M, second wave PD-1 development deal with Sorrento

9 years ago

Sucampo shutters development effort after lead drug flops in back-to-back studies

9 years ago

FDA offers Novartis a thumbs-up on Enbrel biosimilar as Amgen plays offense/defense simultaneously

9 years ago

Celyad bounces back from heart study flop to ink a $312M I/O deal with Ono

9 years ago

Juno scrambles to avoid being crushed by a hold, but experts question its best case scenario

9 years ago

GlaxoSmithKline cautiously follows Sanofi, ramps up a new project for Zika with the NIH

9 years ago

Amgen tees up a swift approval for a franchise destroyer aimed at AbbVie’s $14B drug Humira

9 years ago

Juno’s lead CAR-T slammed with a clinical hold in the last lap ahead of FDA filing

9 years ago

New U.K. translational research effort will test if ketamine can halt alcoholism

9 years ago

First page Previous page 326 327 328329330 331 Next page Last page